Is Valiant Organics overvalued or undervalued?

As of 28 October 2025, Valiant Organics has moved from a very attractive to an attractive valuation grade. The company is currently considered overvalued, given its high PE ratio of 173.65, an EV to EBIT of 42.55, and a PEG ratio of 1.31. In comparison, its peers such as Cipla and Dr. Reddy's Labs have significantly lower PE ratios of 23.52 and 18.66, respectively, indicating that Valiant Organics is trading at a premium relative to these competitors.
Despite a recent stock price increase of 2.99% over the past week, the longer-term performance shows a decline of 20.33% over the past year, which contrasts sharply with the Sensex's positive return of 5.78% during the same period. This discrepancy further supports the conclusion that Valiant Organics is overvalued in the current market environment.